NeoGenomics, Inc. (NEO) News
Filter NEO News Items
NEO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NEO News From Around the Web
Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.
NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesAlthough the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
NeoGenomics Reports Second Quarter 2023 ResultsNeoGenomics, Inc. (NASDAQ:NEO) (the"Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022. |
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast CancerNeoGenomics, Inc. (NASDAQ:NEO),a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection. |
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Company management will host a webcast and conference call that day at 8:30 a.m. |
NeoGenomics Expands Board of Directors with Appointments of Three Independent DirectorsNeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. |
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial CoverageNeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD) and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California. |
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is LackingWhen close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S... |
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast CancerNeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. |
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare ConferenceNeoGenomics, Inc. (NASDAQ:NEO),a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California. |
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCONeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting taking place June 2-6 in Chicago, Illinois. |